An X-ray and γ-ray combination strategy to exploit steep dose gradients for improved prostate cancer radiotherapy: A dosimetric comparison of Taichi Pro and Halcyon.
[PURPOSE] This study aimed to evaluate a novel technological platform, Taichi Pro-which integrates a 6 MV flattening filterfree linear accelerator with a 18 source Rotating Gamma System (RGS) to gener
- p-value P < 0.001
APA
Li K, Yin Y, et al. (2026). An X-ray and γ-ray combination strategy to exploit steep dose gradients for improved prostate cancer radiotherapy: A dosimetric comparison of Taichi Pro and Halcyon.. Journal of applied clinical medical physics, 27(3), e70532. https://doi.org/10.1002/acm2.70532
MLA
Li K, et al.. "An X-ray and γ-ray combination strategy to exploit steep dose gradients for improved prostate cancer radiotherapy: A dosimetric comparison of Taichi Pro and Halcyon.." Journal of applied clinical medical physics, vol. 27, no. 3, 2026, pp. e70532.
PMID
41761597
Abstract
[PURPOSE] This study aimed to evaluate a novel technological platform, Taichi Pro-which integrates a 6 MV flattening filterfree linear accelerator with a 18 source Rotating Gamma System (RGS) to generate steep dose gradients via multisource focused γ-rays and noncoplanar arcs-for precision radiotherapy in prostate cancer. The work provides evidence to support the clinical adoption of hybridmodality radiotherapy devices.
[METHODS] Fifteen prostate cancer patients were enrolled. For each patient, a dual-modality Taichi Pro plan (RGS focused on the planning gross tumor volume (PGTV) + Linac covering the planning target volume (PTV)) and a Halcyon photon plan (three-arc VMAT) were designed while maintaining clinically tolerable dose to organs at risk (OAR). Comparative assessments included planning target volume (PTV and PGTV) metrics (D, D, homogeneity index HI, conformity index CI), OAR doses (rectum V/V/D, bladder V, testis D, etc.) and delivery efficiency to evaluate the ability to escalate target dose while sparing adjacent OARs.
[RESULTS] All plans met institutional clinical constraints. Taichi Pro significantly increased PGTV D (79.48 Gy ± 1.75 Gy) compared to Halcyon (73.25 Gy ± 0.55 24 Gy, P < 0.001) and D (122.74 Gy ± 8.69 Gy) compared to Halcyon (76.15 Gy ± 0.79 Gy, P < 0.001), albeit poorer homogeneity (HI: 0.50 ± 0.09 for Taichi Pro vs. 0.06 ± 0.01 for Halcyon, though within clinically acceptable limits). Taichi Pro significantly reduced rectum V (3.97% ± 3.25% vs. Halcyon 7.46% ± 4.78%, P = 0.016), and D (61.61 Gy ± 5.01 Gy vs. Halcyon 65.29 Gy ± 4.52 Gy, P = 0.040). Taichi Pro also significantly reduced testis D (2.39 ± 1.99 Gy) compared to (3.17 Gy ± 1.40 Gy, P = 0.006). Halcyon demonstrated significantly shorter beam-on time (1.81 ± 0.23 minutes vs. 5.05 ± 1.59 minutes for Taichi Pro, P < 0.001).
[CONCLUSION] Utilizing the steep dose gradient characteristic of the RGS, the Taichi Pro dual-modality system effectively achieved target dose escalation while simultaneously improving sparing of adjacent OARs. This approach holds the potential for enhancing patient treatment outcomes and quality of life.
[METHODS] Fifteen prostate cancer patients were enrolled. For each patient, a dual-modality Taichi Pro plan (RGS focused on the planning gross tumor volume (PGTV) + Linac covering the planning target volume (PTV)) and a Halcyon photon plan (three-arc VMAT) were designed while maintaining clinically tolerable dose to organs at risk (OAR). Comparative assessments included planning target volume (PTV and PGTV) metrics (D, D, homogeneity index HI, conformity index CI), OAR doses (rectum V/V/D, bladder V, testis D, etc.) and delivery efficiency to evaluate the ability to escalate target dose while sparing adjacent OARs.
[RESULTS] All plans met institutional clinical constraints. Taichi Pro significantly increased PGTV D (79.48 Gy ± 1.75 Gy) compared to Halcyon (73.25 Gy ± 0.55 24 Gy, P < 0.001) and D (122.74 Gy ± 8.69 Gy) compared to Halcyon (76.15 Gy ± 0.79 Gy, P < 0.001), albeit poorer homogeneity (HI: 0.50 ± 0.09 for Taichi Pro vs. 0.06 ± 0.01 for Halcyon, though within clinically acceptable limits). Taichi Pro significantly reduced rectum V (3.97% ± 3.25% vs. Halcyon 7.46% ± 4.78%, P = 0.016), and D (61.61 Gy ± 5.01 Gy vs. Halcyon 65.29 Gy ± 4.52 Gy, P = 0.040). Taichi Pro also significantly reduced testis D (2.39 ± 1.99 Gy) compared to (3.17 Gy ± 1.40 Gy, P = 0.006). Halcyon demonstrated significantly shorter beam-on time (1.81 ± 0.23 minutes vs. 5.05 ± 1.59 minutes for Taichi Pro, P < 0.001).
[CONCLUSION] Utilizing the steep dose gradient characteristic of the RGS, the Taichi Pro dual-modality system effectively achieved target dose escalation while simultaneously improving sparing of adjacent OARs. This approach holds the potential for enhancing patient treatment outcomes and quality of life.
MeSH Terms
Humans; Male; Prostatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Radiotherapy Dosage; Organs at Risk; Radiotherapy, Intensity-Modulated; Particle Accelerators; Gamma Rays; X-Rays; Radiometry
같은 제1저자의 인용 많은 논문 (5)
- Traditional Cox regression outperforms large language models in predicting long-term progression of intermediate to advanced hepatocellular carcinoma.
- [Expression of Concern] Leptin promotes breast cancer cell migration and invasion via IL‑18 expression and secretion.
- Regorafenib and Nifuroxazide exert enhanced suppression of hepatocellular carcinoma by inhibiting STAT3 and immune remodeling.
- Revisiting Gender Differences in Gastric Cancer Prevention With Helicobacter pylori Eradication Therapy.
- Perioperative immunotherapy for hepatocellular carcinoma: adjuvant, neoadjuvant, and biomarker-guided strategies.